Currently available options for reversal of TSOACs are limited. However, specific antidotes are in the pipeline and were the subject of this recent review.
They include:
PRT064445 (Portola Pharmaceuticals)
A recombinant Xa variant. Reverses anti Xa agents.
aDabi-Fab (Boehringer Ingelheim)
A humanized Fab fragment for reversal of dabigatran.
PER977 (Perosphere Inc and Daiichi Sankyo)
A small synthetic molecule which is a broad spectrum antidote, binding TSOACs, fondaparinux and low–molecular-weight heparins.
No comments:
Post a Comment